Desmopressin
(Synonyms: 去氨加压素,DDAVP) 目录号 : GC12303
A vasopressin receptor agonist
Cas No.:16679-58-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Desmopressin (dDAVP) is a synthetic peptide analog of natural pituitary hormone 8-arginine vasopressin (ADH) with hemostatic and anti-diuretic properties [1].
Desmopressin reduced the formation of lung nodules in F3II tumor cell injected BALB/c mice. In vitro, desmopressin blocked the F3II cell colony formation. Desmopressin could inhibit metastasis formation on V2 vasopressin receptors in both endothelial and cancer cells [1].
Desmopressin has been proved to increase the release of platelet adhesion promoting factors which is most likely von Willebrand factor (VWF), from endothelial cells (ECs). However, desmopressin had no direct effect on platelets [2].
The administration of desmopressin agglomerates in rats significantly reduced the urine production [3]. Apart from these, rats treated by desmopressin had demonstrated a stronger Pimonidazole staining in the outer and inner medulla compared to control. Desmopressin-treated rats revealed nuclear accumulation in the papilla, which was confirmed by HIF-1α immunostaining. Desmopressin-treated animals had shown a significant increase of HIF-target genes in the group of Desmopressin-regulated gene products including insulin-like growth factor binding proteins 1 and 3, fibronectin, hexokinase 2, angiopoietin 2, cathepsin D and cyclooxygenase 2. Desmopressin had been shown to cause the renal urine concentrating mechanism, leading to an upregulation of hypoxia-inducible gene expression and renal medullary hypoxia [4].
References:
1.Garona J1, Pifano M1, Scursoni AM2, Gomez DE1, Alonso DF3, Ripoll GV1.Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. Anticancer Res. 2014 Sep;34(9):4761-5.
2.Calmer S1, Ferkau A, Larmann J, Johanning K, Czaja E, Hagl C, Echtermeyer F, Goudeva L, Heuft HG, Theilmeier G. Desmopressin (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro. Platelets. 2014;25(1):8-15.
3.Balducci AG1, Ferraro L, Bortolotti F, Nastruzzi C, Colombo P, Sonvico F, Russo P, Colombo G. Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats. Int J Pharm. 2013 Jan 20;440(2):154-60.
4.Dietrich A1, Mathia S, Kaminski H, Mutig K, Rosenberger C, Mrowka R, Bachmann S, Paliege A. Chronic activation of vasopressin V2 receptor signalling lowers renal medullary oxygen levels in rats. Acta Physiol (Oxf). 2013 Apr;207(4):721-31.
| Cas No. | 16679-58-6 | SDF | |
| 别名 | 去氨加压素,DDAVP | ||
| 化学名 | 1-(7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-N-(1-((2-amino-2-oxoethyl)amino)-5-((diaminomethylene)amino)-1-oxopentan-2-yl)pyrrolidine-2-ca | ||
| Canonical SMILES | O=C(C1CSSCCC(NC(CC2=CC=C(O)C=C2)C(NC(CC3=CC=CC=C3)C(NC(CCC(N)=O)C(NC(CC(N)=O)C(N1)=O)=O)=O)=O)=O)N4C(C(NC(C(NCC(N)=O)=O)CCC/N=C(N)\N)=O)CCC4 | ||
| 分子式 | C46H64N14O12S2 | 分子量 | 1069.22 |
| 溶解度 | DMF: 1 mg/ml,DMSO: 5 mg/ml,PBS (pH 7.2): 2 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9353 mL | 4.6763 mL | 9.3526 mL |
| 5 mM | 0.1871 mL | 0.9353 mL | 1.8705 mL |
| 10 mM | 0.0935 mL | 0.4676 mL | 0.9353 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。